Headquarters: Barcelona, Spain
Founded: 1959
Ticker: Private (family-owned)
Website: ferrer.com
Ferrer Internacional is a Spanish pharmaceutical company headquartered in Barcelona, founded in 1959. The company focuses on specialty pharmaceuticals, medical diagnostics, and food health products. Ferrer is best known in the neurodegeneration space for developing FNP-223 (formerly ASN-561), an oral O-GlcNAcase (OGA) inhibitor being evaluated in the PROSPER Phase 2 trial for progressive supranuclear palsy (PSP)[1].
| Attribute | Details |
|---|---|
| Mechanism | O-GlcNAcase (OGA) inhibitor |
| Target | OGA enzyme — increases tau O-GlcNAcylation |
| Indication | Progressive Supranuclear Palsy (PSP) |
| Phase | Phase 2 |
| Trial | PROSPER (NCT06355531) |
| Enrollment | 241 patients |
| Status | Active, results expected late 2026/early 2027 |
PROSPER Trial:
Why PSP?
Ferrer acquired the OGA inhibitor program (originally ASN-561) and advanced it through Phase 2 development. The company has positioned FNP-223 as a potential first-in-class therapy for PSP, a rare but devastating neurodegenerative disorder.
Strategic Importance: